Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Oxford University COSIE study (COvid-19, Social Isolation and Emotion) is an online study which asked people about their experiences during the coronavirus lockdown in late April 2020, while also using objective tests of psychological function to measure vulnerability to mental illness such as depression.

Figure 1: Oxford University COSIE study sample

COVID-19 will have long lasting effects on mental health, both directly, as a result of infection, and indirectly, as a result of isolation. There is an urgent global need to identify the best interventions to help mitigate these effects.  However, without understanding the mechanisms of risk and resilience in this unique situation it is difficult to determine the best treatments. 

The COSIE study is designed to investigate the effect of COVID-19 on mental health and wellbeing. Study leads Professor Catherine Harmer and Dr Susannah Murphy (Department of Psychiatry) recruited a uniquely characterised sample of the population (Figure 1) that will be assessed at regular intervals over the next few months, as the global situation evolves.

Read the full story of the Department of Psychiatry website

Similar stories

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

World’s largest clinical trial for COVID-19 treatments expands internationally

Clinical Trials Coronavirus COVID-19 General

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.

Reprogramming tumour cells using an antimalarial drug

General Research

Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.